Pawlak-Adamska Edyta, Frydecka Irena, Bolanowski Marek, Tomkiewicz Anna, Jonkisz Anna, Karabon Lidia, Partyka Anna, Nowak Oskar, Szalinski Marek, Daroszewski Jacek
Department of Experimental Therapy, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, R. Weigl 12, Wroclaw, 53-114, Poland.
Department of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, L. Pasteur 4, Wroclaw, 50-367, Poland.
Endocrine. 2017 Jan;55(1):186-199. doi: 10.1007/s12020-016-1096-1. Epub 2016 Sep 16.
Graves' disease, an autoimmune disease with heterogeneous symptoms including Graves' orbitopathy, has a combined genetic/environmental background, where variations within CD28/CTLA-4/ICOS genes are considered as disease markers.Association of CD28c.17+3T>C(rs3116496), CTLA-4g.319C>T(rs5742909), CTLA-4c.49A>G(rs231775), CTLA-4g.*642AT(8_33), CT60(rs3087243), Jo31(rs11571302), ICOSc.1554+4GT(8_15) polymorphisms with susceptibility to Graves' disease and clinical outcome was investigated. The study group comprised of 561 Polish Caucasians, including 172 unrelated Graves' disease patients. CTLA-4c.49A>G, CTLA-4g.319C>T, and CT60 were genotyped by PCR-RFLP; Jo31 and CD28c.17+3C>T by minisequencing; CTLA-4g.*642AT(8_33) and ICOSc.1554+4GT(8_15)-PCR and fluorescence-based technique. CD28c.17+3T>C(rs3116496)T/CTLA-4g.319C>T(rs5742909)C/CTLA-4c.49A>G(rs231775)G/CTLA-4g.*642AT(8_33)(AT)/CT60(rs3087243)G/Jo31(rs11571302)G/ICOSc.1554+4GT(8_15)(m) and TCA(AT)GT(m) haplotypes increased risk of Graves' disease, especially in males, as well as overall Graves' orbitopathy development with severe outcome. TCG(AT)GG(l) haplotype increased risk of Graves' disease and reduced the chance of successful medical treatment. Although this haplotype was mainly observed in patients without signs of Graves' orbitopathy, if Graves' orbitopathy developed it favored a Graves' orbitopathy outcome. Haplotype TCA(AT)GT(m) increased Graves' disease risk in women and, in all patients, was linked to Graves' disease without Graves' orbitopathy. TCG(AT)GG(m) haplotype was predominantly observed in patients without Graves' orbitopathy, whereas TCA(AT)GG(m) was absent in those patients. TCA(AT)GG(m) occurred in patients with a mild Graves' orbitopathy outcome. The marker CTLA-4g.*642AT(8_33) was the only independent Graves' disease risk factor, whereas CT60 was an independent factor for disease progression. Sporadic Graves' disease was related to presence of CTLA-4c.49A>G[A] and the rare CTLA-4g.319C>T[T] allele variant. Familial background of the disease was exclusively associated with CTLA-4g.*642AT(8_33)[AT]/[AT] genotype. CD28/CTLA-4/ICOS loci may confer inherited susceptibility to Graves' disease or may be involved in susceptibility to Graves' disease and play a pathogenetic role.
格雷夫斯病是一种自身免疫性疾病,症状多样,包括格雷夫斯眼眶病,具有遗传/环境综合背景,其中CD28/CTLA - 4/ICOS基因内的变异被视为疾病标志物。研究了CD28 c.17 + 3T>C(rs3116496)、CTLA - 4 g.319C>T(rs5742909)、CTLA - 4 c.49A>G(rs231775)、CTLA - 4 g.*642AT(8_33)、CT60(rs3087243)、Jo31(rs11571302)、ICOS c.1554 + 4GT(8_15)多态性与格雷夫斯病易感性及临床结局的关系。研究组包括561名波兰白种人,其中172名无亲缘关系的格雷夫斯病患者。CTLA - 4 c.49A>G、CTLA - 4 g.319C>T和CT60通过PCR - RFLP进行基因分型;Jo31和CD28 c.17 + 3C>T通过微测序法;CTLA - 4 g.*642AT(8_33)和ICOS c.1554 + 4GT(8_15)采用PCR和基于荧光的技术。CD28 c.17 + 3T>C(rs3116496)T/CTLA - 4 g.319C>T(rs5742909)C/CTLA - 4 c.49A>G(rs231775)G/CTLA - 4 g.*642AT(8_33)(AT)/CT60(rs3087243)G/Jo31(rs11571302)G/ICOS c.1554 + 4GT(8_15)(m)和TCA(AT)GT(m)单倍型增加了格雷夫斯病的风险,尤其是男性,以及总体严重结局的格雷夫斯眼眶病的发生风险。TCG(AT)GG(l)单倍型增加了格雷夫斯病的风险,并降低了药物治疗成功的几率。虽然这种单倍型主要在无格雷夫斯眼眶病体征的患者中观察到,但如果发生格雷夫斯眼眶病,则更易出现格雷夫斯眼眶病结局。单倍型TCA(AT)GT(m)增加了女性患格雷夫斯病的风险,并且在所有患者中,与无格雷夫斯眼眶病的格雷夫斯病相关。TCG(AT)GG(m)单倍型主要在无格雷夫斯眼眶病的患者中观察到,而TCA(AT)GG(m)在这些患者中不存在。TCA(AT)GG(m)出现在格雷夫斯眼眶病结局较轻的患者中。标志物CTLA - 4 g.*642AT(8_33)是唯一独立的格雷夫斯病风险因素,而CT60是疾病进展的独立因素。散发性格雷夫斯病与CTLA - 4 c.49A>G[A]和罕见的CTLA - 4 g.319C>T[T]等位基因变异的存在有关。该疾病的家族背景仅与CTLA - 4 g.*642AT(8_33)[AT]/[AT]基因型相关。CD28/CTLA - 4/ICOS基因座可能赋予格雷夫斯病遗传易感性,或可能参与格雷夫斯病的易感性并发挥致病作用。